

Friday, 13 October 2017

- 08.45 – 09.00 Opening and objectives**
C. Chapple, Sheffield (GB)
F. Cruz, Porto (PT)
R. Djinic, Belgrade (RS)
- 09.00 – 09.30 State-of-the-art lecture:**
Can OAB be a consequence of an unrecognised urinary infection?
Chair: C. Chapple, Sheffield (GB)
For: A. Tubaro, Rome (IT)
Against: F. Van Der Aa, Leuven (BE)
- 09.30 – 11.00 Why do clinical trials not correlate with real life clinical practice?**
Chair: C. Chapple, Sheffield (GB)
- 09.30 – 09.35 Setting the scene**
C. Chapple, Sheffield (GB)
- 09.35 – 09.50 What are the options for OAB patients with partial response to antimuscarinics?**
F. Van Der Aa, Leuven (BE)
- 09.50 – 10.05 Are beta 3 agonists ready to be first line option?**
P. van Kerrebroeck, Maastricht (NL)
- 10.05 – 10.20 OAB refractory to oral medication: Botulinum toxin or sacral neuromodulation?**
S. Arlandis, Valencia (ES)
- 10.20 – 10.35 OAB treatment in elderly patients**
M. Kirby, Baldock (GB)
- 10.35 – 10.50 Interactive clinical case discussion**
All faculty
- 10.50 – 11.00 Take home message**
C. Chapple, Sheffield (GB)
- 11.00 – 11.30 Coffee break**
- 11.30 – 12.00 Why is low persistence on treatment a problem for OAB patients?**
Chair: F. Cruz, Porto (PT)
Discussant: A. Wagg, Alberta (CA)
- 12.00 – 13.00 The Underactive Bladder**
Chair: P. Van Kerrebroeck, Maastricht (NL)
- 12.00 - 12.20 Consensus report on definition**
P. Van Kerrebroeck, Maastricht (NL)
- 12.20 - 12.40 Therapeutic options**
C. Chapple, Sheffield (UK)
- 12.40 - 13.00 Case discussion and take home messages**
G. Van Koeveringe, Maastricht (NL)
- 13.00 – 14.00 Lunch & Industry Session/ Meet the expert**

14.00 – 14.30 State-of-the-art lecture: Nocturia affects both men and women!
Case studies – a male patient voiding 4 times a day with nocturia x5 and nocturnal polyuria)
Chair: K-D. Sievert, Salzburg (AT)
Discussant: M.J. Drake, Bristol (GB)

14.30 – 15.30 Female stress urinary incontinence
Chair: F. Cruz, Porto (PT)

14.30 – 14.35 Setting the scene
F. Cruz, Porto (PT)

14.35 – 14.50 Doctor, if I have the operation, will I be cured forever?
Tufan Tarcan, Istanbul (TR)

14.50 – 15.05 Doctor, I had the surgery but I am still leaking
S. Arlandis, Valencia (ES)

15.05 – 15.20 Should POP and SIU be corrected at the same time?
E. Costantini, Perugia (IT)

15.20 – 15.30 Discussion and take home messages
F. Cruz, Porto (PT)

15.30 – 16.00 Coffee break

**16.00 – 16.30 Quality of Life and its assessment in female urology
State of the Art**
Chair: M.J. Drake, Bristol (GB)
L. Cardozo, London (UK)

Parallel session EUGA

16.30 – 17.30 POP and the use of mesh
Chair: L. Cardozo, London (GB)

16.30 – 16.35 Setting the scene
L. Cardozo, London (GB)

16.35 – 16.45 Pelvic organ prolapse in young women: Which strategy?
M. Meschia, Milan (IT)

16.45 – 16.55 Ageing of the pelvic floor
H. Koelbl, Vienna (AT)

16.55 – 17.05 POP surgery. Native tissue repair: Back to the future
S. Salvatore, Milan (IT)

17.05 – 17.15 POP surgery: When and why I choose laparoscopic or vaginal approach
S. Athanasiou, Athens (GR)

17.15 – 17.30 General discussion and take home message
L. Cardozo, London (GB)

Parallel Session ESGURS

16.30 – 17.30 Peyronie's disease
Chair: R. Djjinovic, Belgrade (RS)

16.30 – 16.35 Setting the scene
R. Djjinovic, Belgrade (RS)

- 16.35 – 16.50 **Corporoplasty**
N. Tomada, Porto (PT)
- 16.50 – 17.05 **Doctor, I don't want my penis shortened!**
S. Sansalone, Rome (IT)
- 17.05 – 16.20 **When is a penile prosthesis is indicated?**
J. Romero-Otero, Madrid (ES)
- 17.20– 17.30 **Discussion and take home messages**
R. Djjinovic, Belgrade (RS)

17.30 – 18.30 Industry Session

Saturday 14 October 2017

- 08.00 – 08.30 State-of-the-art lecture: Male incontinence after radical prostatectomy. What should I do?**
Chair: C. Chapple, Sheffield (GB)
Speaker: J. Heesakkers, Nijmegen (NL)
- 08.30 – 10.00 NDO and incontinence**
Chair: T. Kessler, Zurich (CH)
- 08.30 – 08.35 Setting the scene**
T. Kessler, Zurich (CH)
- 08.35 – 08.50 Can I control incontinence with oral medication in MS patients?**
R. Hamid, London (GB)
- 08.50 – 09.05 When is the moment to introduce botulinum toxin in MS patients?**
G. Del Popolo, Florence (IT)
- 09.05 – 09.20 How do I follow-up a patient with NDO and spinal cord injury?**
J. N. Panicker, London (GB)
- 09.20 – 09.35 When do I stop botulinum toxin and offer bladder augmentation?**
Tufan Tarcan, Istanbul (TR)
- 09.35 – 09.55 Interactive clinical case discussion**
U. Mehnert, Zurich (CH)
- 09.55 – 10.00 Take home message**
T. Kessler, Zurich (CH)
- 10.00 – 11.00 Dementia and incontinence**
Chair: J. Heesakkers, Nijmegen (NL)
- 10.00 – 10.05 Setting the scene**
J. Heesakkers, Nijmegen (NL)
- 10.05 – 10.20 Management of urinary incontinence in a patient with Alzheimer's disease**
A. Wagg, Alberta (CA)
- 10.20 – 10.35 Antimuscarinic drugs and brain damage: What is the risk?**
R. Bosch, Utrecht (NL)
- 10.35 – 10.55 Interactive clinical case discussion**
J. Heesakkers, Nijmegen (NL) (asked 24/5)
- 10.55 – 11.00 Take home message**
J. Heesakkers, Nijmegen (NL)

Parallel session ESGURS

08.30 - 11.00 Urethroplasty (semi live surgery)

Chair: R. Djinovic, Belgrade (RS)

08.30 – 09.00 To transect the urethra or not?

L. Martinez Pineiro, Madrid (ES)

09.00 – 09.30 Augmentation or Anastomosis in the borderline case

R. Dahlem, Hamburg (DE)

09.30 – 10.00 Female urethroplasty

C. Chapple, Sheffield (GB)

10.00 – 10.30 Should we ever use penile skin and when?

N. Lumen, Ghent (BE)

10.30 – 11.00 Managing the hypospadiac ‘cripple’

R. Inman, Sheffield (UK)

11.00 – 11.30 Coffee Break

11.30 – 11.50 My patient has a urinary Fistula – what should I do?

State of the Art

Chair: F. Cruz, Porto (PT)

Discussant: G. Kasyan, Moscow (RU)

11.50 – 13.15 My BPH patient needs treatment

Chair: D. Castro Diaz, Tenerife (ES)

11.50 – 11.55 Setting the scene

D. Castro Diaz, Tenerife (ES)

11.55 - 12.10 One drug, two drugs, three drugs? What the EAU guideline tell us

M. Oelke, Hanover (DE)

12.10 - 12.25 Antimuscarinics or beta 3 agonists for males with persistent storage LUTS?

E. Finazzi Agrò, Rome (IT)

12.25 - 12.45 Debate: My BPH patient needs surgery

I prefer LIFT

K-D. Sievert, Salzburg (AT) (7+3 minutes)

TURP is still the gold standard

P. Radziszewski , Warsaw (PL) (7+3 minutes)

12.45 - 13.15 Interactive clinical case discussion and take home messages

D. Castro Diaz, Tenerife (ES)

13.15 – 14.15 Astellas Industry Session

14.15 - 14.45 Challenging cases

State of the Art

Chair: C. Chapple, Sheffield (GB)

Discussant: P. Abrams, Bristol (GB)

- 14.45 – 16.00 Painful Bladder Syndrome (Interstitial cystitis)**
Chair: R. Peeker, Gothenburg (SE)
- 14.45 – 14.50 Setting the scene**
R. Peeker, Gothenburg (SE)
- 14.50 – 15.05 Are we talking about a local or a systemic disease?**
J. Sairanen, Helsinki (FI)
- 15.05 - 15.20 Do mucosal barrier protectors work?**
M. Lazzeri, Florence (IT)
- 15.20 -15.35 Is botulinum toxin A the future magic bullet for the management of BPS/IC?**
P. Radziszewski, Warsaw (PL)
- 15.35 – 15.55 Interactive clinical case discussion**
D. S. Engeler, St. Gallen (CH)
- 15.55 – 16.00 Take home message**
R. Peeker, Gothenburg (SE)
- 16.00 – 16.15 Closure**
C. Chapple, Sheffield (GB)
F. Cruz, Porto (PT)
R. Djinovic, Belgrade (RS)